Concert Pharmaceuticals, Inc. (CNCE) News
Filter CNCE News Items
CNCE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CNCE News Highlights
- CNCE's 30 day story count now stands at 2.
- Over the past 23 days, the trend for CNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SUN are the most mentioned tickers in articles about CNCE.
Latest CNCE News From Around the Web
Below are the latest news stories about CONCERT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNCE as an investment opportunity.
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataLEXINGTON, Mass., February 15, 2023--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata. |
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout OfferConcert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week. |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
Why Concert Pharmaceuticals Stock Rocketed Higher This WeekIf all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Market Intelligence. The two companies didn't hesitate to point out that this is roughly 33% higher than the latter's 30-day-trailing weighted average share price as of Wednesday, Jan. 18. |
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Concert Pharmaceuticals... |
Pharma giant in India buys Concert Pharmaceuticals in $576M dealAn Indian drugmaker will buy Lexington's Concert Pharmaceuticals (NASDAQ: CNCE) in a cash deal valued at an initial $576 million, the two companies announced Thursday. |
India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus MilestonesSun Pharmaceutical Industries Limited, India's top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (NASDAQ: CNCE) for an upfront payment of $8.00 per share, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. Concert is a late-stage biotechno |
UPDATE 2-India's Sun Pharma acquires U.S.-based Concert for $576 mlnSun Pharmaceutical Industries Limited , India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness. The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close. |
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia AreataMUMBAI & LEXINGTON, Mass., January 19, 2023--Sun Pharma to acquire Concert Pharmaceuticals. |
Concert (CNCE) Moves 19.3% Higher: Will This Strength Last?Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |